dave297
05 Nov 2015
Re: information from official Kyorin rep... As Q2 turnover this year was 10mill Euros,ie about 1.35 bill Yen, & growing I suppose it is feasible that our annual turnover in Japan maybe running at 5-6 bill yen + & that assumes quarterly growth of 20%+.With view to Q2 though our annual turnover should certainly be more than 3 bill Y-30bill sounds like a fantasy figure currently, & sadly.I would imagine that asthma is a bigger problem in Japan ( the second biggest market in the world ) due the humidity over the summer months & it should therefore become our biggest market- unless the US is ever opened up to us.
Ambiorix1
05 Nov 2015
Re: information from official Kyorin report ... Caution : the report states 30 billion but this should probably be 3.0 billion Yen.
Ambiorix1
05 Nov 2015
information from official Kyorin report Q3 Flutiform salesSeptember 2014 : 0.9 billion YenSeptember 2015 : 30 billion YenSales increase 216.2%Good news indeed,Ambiorix.
sadoldsod
05 Nov 2015
Re: Time to buy good news re sales in Japan over on the ADVFN site
dave297
05 Nov 2015
Re: Time to buy May be wrong but I seem to remember SKP announcing some time ago that they were cutting out a couple of Trading Updates a year due to the amount of time needed to be devoted to their preparation.Our records must be updated daily & my view is that more information is better than less & I would prefer an update.The next scheduled update may be in respect of the year end,usually announced about 10th Jan-although if we are trading ahead of expectations,which is possible,we may have to issue an update before then.£5 sounds quite attractive compared to our current SP but a bid at that level tomorrow would leave me feeling sold short,despite the profits I would make here.Not about greed but value - IMHO
Ambiorix1
05 Nov 2015
Re: Time to buy BTW, shouldn't we get an Q3 update soon? Last year there has been a trading update in early October.
sadoldsod
05 Nov 2015
lets try again five pounds
sadoldsod
05 Nov 2015
price dont what happened should read £5
sadoldsod
05 Nov 2015
Re: Time to buy Hi Dave like you bought more this week at 320p could have done better dont get it right all the time but like you sometimes you have to take a bit of gamble !!! (dont think this is long term) my largest holding by a long way . £5 looks more tan possible
dave297
05 Nov 2015
Re: Time to buy I take your point Ambiorix & the sensible investor would prefer the portfolio approach & take a 5% yield while also being exposed to the potential growth from those elements of the HBM portfolio.I however , & sometimes to my cost & profit, take a more high risk approach & bought some more SKP earlier this week.I believe that we will be taken over at some stage,particularly if Fluti continues growing strongly, & I am hoping for £10 + rather than the £4+ which could possibly be achieved right now.
Ambiorix1
03 Nov 2015
Re: Time to buy I fully agree with you Dave. If Flutiform is positively making its way on the market and the use of Exparel is extended, the share price of SKP should follow upwards. Actually, SKP is only quoted at a PE of 14 for the end-of-the-year 16 revenues and this share price does not reflect any positive surprises. But your ‘off the radar’ could have another explanation. Funds don’t need to invest in SKP to be major shareholder. An investment in Swiss-quoted HBM could be more rewarding. HBM is main shareholder of SKP (among the biggest participations) and also of Pacira, Ophtotech, Advanced Accelerator and Basilea, and for the latter one an IPO on Nasdaq is expected for the end of this year. Above this, HBM Healthcare pays a serious dividend (the last one being 5%). For a fund or a bigger investor, HBM is a less risky bet on SKP, and the investment is rewarded every year by a hefty dividend. Ambiorix.
dave297
03 Nov 2015
Re: Time to buy Following our substantial re rating over the last two years or so SKP appears to have fallen off the radar of most investors & funds but I,like you , consider us to be currently seriously undervalued & have been increasing my holding again.It is a relief that Exparel is recovering & now seems very likely that our next milestone will be paid, probably next year & if our next trading announcement shows that sales of Flutiform are continuing to grow strongly our re rating may continue towards brokers valuations of 460p & beyond.There also remains scope for some of our other products & products under development to surprise on the upside.
Ambiorix1
02 Nov 2015
Time to buy At this price Skyepharma seems undervalued again because of this
acira delivered Q3 EPS and revenue ahead of expected results. The company is set to favourably resolve the warning letter issue with the FDA in the following weeks and therefore Exparel is well positioned for growth in 2016 and beyond. This simply means more royalties for Skyepharma to come which, from my point of view, is not reflected by the current share price. Indeed, things are looking up for Pacira. After some bad news over the last few months, the company's prospects have improved in the last couple of weeks. Exparel's growth in the third quarter was encouraging, especially considering all the headwinds the company was facing and the fact that Q3 is usually a slow quarter. Pacira is also in active discussions with the FDA after filing a lawsuit against the agency, which removed its warning letter, and indicates the issue will be resolved favourably for Pacira. The favourable resolution with the FDA could again accelerate Exparel's growth in the following quarters. Pacira plans to focus on development activities around Exparel. The market's reaction in the US following the earnings report was very positive and the stock probably bottomed. This should also be reflected in Skyepharma’s share price, but is hasn’t yet. Time to buy.Ambiorix.
dave297
12 Oct 2015
Re: buy Having bought more @ about 260p in Aug I added again last week @ under 340p.I believe that there remains scope for a profits upgrade before the year end & there is always the possibility of something unexpectedly positive being announced( new product,new deal,existing product performing better than expected, partner for Fluti in US).We have re rated substantially over the last 2 years but we are a substantially different company now with no debt,new products & increasing revenues, profitability & cash flows & ,at some point,we may be view as a tasty morsel for 1 of the much larger companies in our sector-I just hope ,if that happens,it is for a decent price,ie much more than 460p
Ripley94
20 Sep 2015
Re: buy motley fool 4 Sept 15
